botensilimab,balstilimab
agenus
90-95% of metastatic crc is microsatellite stable (mss). our global phase 2 trial in mss crc is planned to begin later this year. #cancerresearch #esmogi
Our goal is to treat cancers with novel combinations using our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines & adjuvants